Jeremy M Schraw1,2, Tania A Desrosiers3, Wendy N Nembhard4, Peter H Langlois5, Robert E Meyer6,7, Mark A Canfield5, Sonja A Rasmussen8,9, Tiffany M Chambers2,10, Logan G Spector11, Sharon E Plon10,12, Philip J Lupo1,2,10. 1. Department of Medicine, Baylor College of Medicine, Houston, Texas. 2. Center for Epidemiology and Population Health, Baylor College of Medicine, Houston, Texas. 3. Department of Epidemiology, University of North Carolina, Chapel Hill, North Carolina. 4. Department of Epidemiology, University of Arkansas for Medical Sciences, Little Rock, Arkansas. 5. Birth Defects Epidemiology and Surveillance Branch, Department of State Health Services, Austin, Texas. 6. Department of Maternal and Child Health, University of North Carolina, Chapel Hill, North Carolina. 7. State Center for Health Statistics, North Carolina Division of Public Health, Raleigh, North Carolina. 8. Department of Pediatrics, University of Florida College of Medicine, Gainesville, Florida. 9. Department of Epidemiology, University of Florida College of Medicine and College of Public Health and Health Professions, Gainesville, Florida. 10. Department of Pediatrics, Baylor College of Medicine, Houston, Texas. 11. Department of Pediatrics, University of Minnesota, Minneapolis, Minnesota. 12. Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, Texas.
Abstract
BACKGROUND: Birth defects are established risk factors for childhood cancer. Nonetheless, cancer epidemiology in children with birth defects is not well characterized. METHODS: Using data from population-based registries in 4 US states, this study compared children with cancer but no birth defects (n = 13,111) with children with cancer and 1 or more nonsyndromic birth defects (n = 1616). The objective was to evaluate cancer diagnostic characteristics, including tumor type, age at diagnosis, and stage at diagnosis. RESULTS: Compared with the general population of children with cancer, children with birth defects were diagnosed with more embryonal tumors (26.6% vs 18.7%; q < 0.001), including neuroblastoma (12.5% vs 8.2%; q < 0.001) and hepatoblastoma (5.0% vs 1.3%; q < 0.001), but fewer hematologic malignancies, including acute lymphoblastic leukemia (12.4% vs 24.4%; q < 0.001). In age-stratified analyses, differences in tumor type were evident among children younger than 1 year and children 1 to 4 years old, but they were attenuated among children 5 years of age or older. The age at diagnosis was younger in children with birth defects for most cancers, including leukemia, lymphoma, astrocytoma, medulloblastoma, ependymoma, embryonal tumors, and germ cell tumors (all q < 0.05). CONCLUSIONS: The results indicate possible etiologic heterogeneity in children with birth defects, have implications for future surveillance efforts, and raise the possibility of differential cancer ascertainment in children with birth defects. LAY SUMMARY: Scientific studies suggest that children with birth defects are at increased risk for cancer. However, these studies have not been able to determine whether important tumor characteristics, such as the type of tumor diagnosed, the age at which the tumor is diagnosed, and the degree to which the tumor has spread at the time of diagnosis, are different for children with birth defects and children without birth defects. This study attempts to answer these important questions. By doing so, it may help scientists and physicians to understand the causes of cancer in children with birth defects and diagnose cancer at earlier stages when it is more treatable.
BACKGROUND: Birth defects are established risk factors for childhood cancer. Nonetheless, cancer epidemiology in children with birth defects is not well characterized. METHODS: Using data from population-based registries in 4 US states, this study compared children with cancer but no birth defects (n = 13,111) with children with cancer and 1 or more nonsyndromic birth defects (n = 1616). The objective was to evaluate cancer diagnostic characteristics, including tumor type, age at diagnosis, and stage at diagnosis. RESULTS: Compared with the general population of children with cancer, children with birth defects were diagnosed with more embryonal tumors (26.6% vs 18.7%; q < 0.001), including neuroblastoma (12.5% vs 8.2%; q < 0.001) and hepatoblastoma (5.0% vs 1.3%; q < 0.001), but fewer hematologic malignancies, including acute lymphoblastic leukemia (12.4% vs 24.4%; q < 0.001). In age-stratified analyses, differences in tumor type were evident among children younger than 1 year and children 1 to 4 years old, but they were attenuated among children 5 years of age or older. The age at diagnosis was younger in children with birth defects for most cancers, including leukemia, lymphoma, astrocytoma, medulloblastoma, ependymoma, embryonal tumors, and germ cell tumors (all q < 0.05). CONCLUSIONS: The results indicate possible etiologic heterogeneity in children with birth defects, have implications for future surveillance efforts, and raise the possibility of differential cancer ascertainment in children with birth defects. LAY SUMMARY: Scientific studies suggest that children with birth defects are at increased risk for cancer. However, these studies have not been able to determine whether important tumor characteristics, such as the type of tumor diagnosed, the age at which the tumor is diagnosed, and the degree to which the tumor has spread at the time of diagnosis, are different for children with birth defects and children without birth defects. This study attempts to answer these important questions. By doing so, it may help scientists and physicians to understand the causes of cancer in children with birth defects and diagnose cancer at earlier stages when it is more treatable.
Authors: María Elena Martínez; Giovanna I Cruz; Abenaa M Brewster; Melissa L Bondy; Patricia A Thompson Journal: Cancer Epidemiol Biomarkers Prev Date: 2010-09-24 Impact factor: 4.254
Authors: Paul Graham Fisher; Peggy Reynolds; Julie Von Behren; Suzan L Carmichael; Sonja A Rasmussen; Gary M Shaw Journal: J Pediatr Date: 2012-01-11 Impact factor: 4.406
Authors: David Malkin; Kim E Nichols; Joshua D Schiffman; Sharon E Plon; Garrett M Brodeur Journal: Clin Cancer Res Date: 2017-11-01 Impact factor: 12.531
Authors: Michael J Davies; Vivienne M Moore; Kristyn J Willson; Phillipa Van Essen; Kevin Priest; Heather Scott; Eric A Haan; Annabelle Chan Journal: N Engl J Med Date: 2012-05-05 Impact factor: 91.245
Authors: R Thomas Collins; Julie Von Behren; Wei Yang; Suzan L Carmichael; Peggy Reynolds; Paul G Fisher; Gary M Shaw Journal: Birth Defects Res Date: 2018-10-16 Impact factor: 2.344
Authors: Michael D Taylor; Paul A Northcott; Andrey Korshunov; Marc Remke; Yoon-Jae Cho; Steven C Clifford; Charles G Eberhart; D Williams Parsons; Stefan Rutkowski; Amar Gajjar; David W Ellison; Peter Lichter; Richard J Gilbertson; Scott L Pomeroy; Marcel Kool; Stefan M Pfister Journal: Acta Neuropathol Date: 2011-12-02 Impact factor: 17.088
Authors: Talita Aguiar; Anne Teixeira; Marília O Scliar; Juliana Sobral de Barros; Renan B Lemes; Silvia Souza; Giovanna Tolezano; Fernanda Santos; Israel Tojal; Monica Cypriano; Silvia Regina Caminada de Toledo; Eugênia Valadares; Raquel Borges Pinto; Osvaldo Afonso Pinto Artigalas; Joaquim Caetano de Aguirre Neto; Estela Novak; Lilian Maria Cristofani; Sofia M Miura Sugayama; Vicente Odone; Isabela Werneck Cunha; Cecilia Maria Lima da Costa; Carla Rosenberg; Ana Krepischi Journal: Front Genet Date: 2022-04-12 Impact factor: 4.772